Synthesis and initial evaluation of novel, non-peptidic antagonists of the αv-integrins αvβ3 and αvβ5

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 2, 2009, Pages 352-355

  Letourneau, Jeffrey J ^a   Liu, Jinqi ^a   Ohlmeyer, Michael H J ^a   Riviello, Chris ^a   Rong, Yajing ^a   Li, Hong ^a   Appell, Kenneth C ^a   Bansal, Shalini ^a   Jacob, Biji ^a   Wong, Angela ^a   Webb, Maria L ^a  

^a PHARMACOPEIA INC   (United States)

Author keywords

Inhibitors; Integrin

Indexed keywords

ALPHAVBETA5 INTEGRIN; CD51 ANTIGEN; INTEGRIN INHIBITOR; PEPTIDE LIBRARY; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EVALUATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; STRUCTURE ACTIVITY RELATION;

BIOLOGICAL AVAILABILITY; CELL LINE; HUMANS; INTEGRIN ALPHAVBETA3; MACROCYCLIC COMPOUNDS; RECEPTORS, VITRONECTIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57749118590     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.074     Document Type: Article

References (28)

1. Hynes R.O. Cell 69 (1992) 11
2. Trikha M., Zhou Z., Timar J., Raso E., Kennel M., Emmell E., and Nakada M.T. Cancer Res. 62 (2002) 2824
3. Kumar C.C., Malkowski M., Yin Z., Tanghetti E., Yaremko B., Nechuta T., Varner J., Liu M., Smith E.M., Neustadt B., Presta M., and Armstrong L. Cancer Res. 61 (2001) 2232
4. Stupp R., and Ruegg C. J. Clin. Oncol. 25 (2007) 1637
5. Reardon D.A., Nabors B.L., Stupp R., and Mikkelsen T. Expert Opin. Investig. Drugs 17 (2008) 1225
6. Nagarajan S.R., Devadas B., Malecha J.W., Lu H.-F., Ruminski P.G., Rico J.G., Rogers T.E., Marrufo L.D., Collins J.T., Kleine H.P., Lantz M.K., Zhu J., Green N.F., Russell M.A., Landis B.H., Miller L.M., Meyer D.M., Duffin T.D., Engleman V.W., Finn M.B., Freeman S.K., Griggs D.W., Williams M.L., Nickols M.A., Pegg J.A., Shannon K.E., Steininger C., Westlin M.M., Nickols G.A., and Keene J.L. Bioorg. Med. Chem. 15 (2007) 3783
7. Manzoni L., Bassanini M., Belvisi L., Motto I., Scolastico C., Castorina M., and Pisano C. Eur. J. Org. Chem. 8 (2007) 1309
8. Marugan J.J., Manthey C., Anaclerio B., Lafrance L., Lu T., Markotan T., Leonard K.A., Crysler C., Eisennagel S., Dasgupta M., and Tomczuk B. J. Med. Chem. 48 (2005) 926
9. Leonard K., Pan W., Anaclerio B., Gushue J.M., Guo Z., DesJarlais R.L., Chaikin M.A., Lattanze J., Crysler C., Manthey C.L., Tomczuk B.E., and Marugan J.J. Bioorg. Med. Chem. Lett. 15 (2005) 2679
10. Zartman A.E., Duong L.T., Fernandez-Metzler C., Hartman G.D., Leu C.-T., Prueksaritanont T., Rodan G.A., Rodan S.B., Duggan M.E., and Meissner R.S. Bioorg. Med. Chem. Lett. 15 (2005) 1647
11. For an excellent review see:. Cacciari B., and Spalluto G. Curr. Med. Chem. 12 (2005) 51 (and references therein)
12. Meissner R.S., Perkins J.J., Duong L.T., Hartman G.D., Hoffman W.F., Huff J.R., Ihle N.C., Leu C.T., Nagy R.M., Naylor-Olsen A., Rodan G.A., Whitman D.B., Wesolowsky G.A., and Duggan M.E. Bioorg. Med. Chem. Lett. 12 (2002) 25
13. Baldwin J.J., Burbaum J.J., Henderson I., and Ohlmeyer M.H.J. J. Am. Chem. Soc. 117 (1995) 5588
14. Ohlmeyer M.H.J., Swanson R.N., Dillard L.W., Reader J.C., Asouline G., Kobayashi R., Wigler M., and Still W.C. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 10922
15. Nestler H.P., Bartlett P.A., and Still W.C. J. Org. Chem. 59 (1994) 4723
16. Kapyla J., Ivaska J., Riikonen R., Nykvist P., Pentikainen O., Johnson M., and Heino M. J. Biol. Chem. 275 (2000) 3348
17. 3) in buffer A plus 20 μM DTPA, 0.05% BSA were then added to the wells followed by 1-h incubation at room temperature. The plate was washed with buffer A. The enhancement solution was added and the fluorescence was measured after 10-min incubation on the shaker.
18. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Deliv. Rev. 23 (1997) 3
19. Physicochemical properties, including FPSA, were calculated using ADME Profiler: Program for discreet compound analysis and calculation of physicochemical properties, version 1.6.0; Pharmacopeia Inc., 2004.
20. Egan W.J., Merz K.M., and Baldwin J.J. J. Med. Chem. 43 (2000) 3867
21. Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., and Kopple K.D. J. Med. Chem. 45 (2002) 2615
22. Letourneau, J. J.; Paradkar, V.; Ohlmeyer, M. H. J.; Dillard, L. W.; Baldwin, J. J.; Riviello, C. M.; Wong, A.; Rong, Y. U.S. Patent 7,365,209, April 29, 2008.
23. Kobayashi S., Ishitani H., Komiyama S., Oniciu D.C., and Katritzky A.R. Tetrahedron Lett. 37 (1996) 3731
24. Kohn E.C., Alessandro R., Spoonster J., Wersto R.P., and Liotta L.A. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 1307
25. 2 for 24 h. The media was then decanted and 200 μL of proliferation media containing EBM-2 plus 2% FBS and 3 ng/mL FGF with the compound was added and the cells were incubated for an additional 48 h. Cells were then fixed with 2.5% glutaraldehyde for 30 min, washed and stained with 0.1% crystal violet. Absorbance at 595 nM was measured after being washed and destained using 10% acetic acid.
26. Yoon M.-J., Cho C.-H., Lee C.S., Jang I.-H., Ryu S.H., and Koh G.Y. Biochem. Biophys. Res. Commun. 308 (2003) 101
27. 2 for 1 h at 37 °C, followed by blocking with 2% BSA in the coating buffer for 1 h at 37 °C. HUVEC cells were then seeded to the upper chamber at 20,000 per well in 100 μL of migration buffer in the presence or absence of the compound. Migration buffer (500 μL) was added to the bottom chamber followed by incubation at 37 °C for 4 h. The non-migrated cells were removed from the upper side of the filters with a cotton ball. The migrated cells were fixed with 2.5% glutaraldehyde followed by washing and staining using 0.1% crystal violet. The stained cells were photographed and analyzed using ScanImage.
28. Chavakis E., Riecke B., Lin J., Linn T., Bretzel R.G., Preissner K.T., Brownlee M., and Hammes H.-P. Diabetologia 45 (2002) 262